Purpose: to evaluate the effectiveness of lowering blood sugar and kidney safety of Dapaggliflozin in patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease (CKD 3A).

Inclusion Criteria

  • Men or women diagnosed with Type 2 Diabetes
  • 18-75 years of age
  • HbA1c: 7%-11%
  • Stable treatment of diabetes which can include: diet and exercise, oral diabetes medication, insulin, or any combination of these treatments
  • Chronic Kidney Disease stage 3A (eGFR of 40-65 mL/min/1.73m²)

Exclusion Criteria

  • Women that are pregnant, breastfeeding or planning to become pregnant in the near future
  • Severe uncontrolled high blood pressure
  • Any serious cardiovascular event within the last 3 months
  • Kidney transplant or history of kidney biopsy
  • Long term treatment with glucocorticoids
  • Use of SGLT-2 inhibitors
  • Cancer within the past 5 years (with the exception of treated basal or squamous cell carcinoma)


Please contact Katarina Vukojicic, Derive research coordinator, for more information:


UNC Diabetes Care Center


If you join Derive, you will receive all medications and supplies at no cost to you.